Table 2. COVID-19 seroprevalence in liver transplant recipients according to potential risk factors and clinical symptoms (N = 213).

	N (%) tested	ELISA IgG positive			VNT positive
		N (%)	95%CI	P	N (%)	95%CI	P
Risk factors
Blood transfusion
Yes	33 (15.5)	6 (18.2)	7.0-35.5	0.889	1 (3.0)	0.1-15.8	0.496
No	180 (84.5)	35 (19.4)	13.9-26.0		3 (1.1)	0.2-3.1
Participation in large community events
Yes	18 (8.5)	4 (22.2)	0.6-47.6	0.785	1 (5.6)	0.1-27.3	0.242
No	195 (91.5)	37 (19.0)	13.7-25.2		2 (1.0)	0.1-3.7
Travelling abroad
Yes	10 (4.7)	4 (40.0)	12.2-73.8	0.194	2 (20.0)	2.5-55.6	0.015
No	203 (95.3)	37 (18.2)	13.2-24.2		2 (1.0)	0.1-3.5
Clinical symptoms
Fever
Yes	34 (15.9)	11 (32.3)	17.4-50.5	0.095	2 (5.9)	0.7-19.7	0.129
No	179 (84.1)	30 (16.7)	11.6-23.1		2 (1.1)	0.1-4.0
Cough
Yes	19 (8.9)	2 (10.5)	1.3-33.1	0.390	2 (10.5)	1.3-33.1	0.047
No	194 (91.1)	39 (20.1)	14.7-26.4		2 (1.0)	0.1-3.7
Breathing difficulties
Yes	13 (6.1)	1 (7.7)	0.2-36.0	0.347	3 (23.1)	0.5-53.8	0.001
No	200 (93.9)	40 (0.2)	14.7-20.2		1 (0.5)	0-2.7
Anosmia
Yes	2 (0.9)	0 (0)	0-8.4*	0.534	0 (0)	0 - 84.1*	1.000
No	211 (99.1)	41 (19.4)	14.3-25.4		4 (1.9)	0.5 - 4.8
Ageusia
Yes	6 (2.8)	1(16.6)	0.4-64.1	0.892	0 (0)	0-45.9*	1.000
No	207 (97.2)	40 (19.3)	14.2-25.4		4 (1.9)	0.5-4.8
Headache
Yes	29 (13.6)	2 (6.9)	0.8-22.8	0.118	0 (0)	0-11.9*	1.000
No	184 (86.4)	39 (21.2)	15.6-27.9		4 (2.2)	0.6-5.5
Muscle aches
Yes	25 (11.7)	4 (16.0)	4.5-36.1	0.708	1 (4.0)	0.1-20.3	0.402
No	188 (88.3)	37 (19.7)	14.3-26.2		3 (1.6)	0.3-4.6
*One-sided 97.5% confidence interval. ELISA - enzyme-linked immunosorbent assay. IgG - immunoglobulin G. VNT - virus neutralization test. P < 0.05 was considered statistically significant.